 | • レポートコード：D0GIR-01509 • 出版社/出版日：GlobalInfoResearch / 2020年9月23日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、106ページ • 納品方法：Eメール • 産業分類：医療、製薬、バイオ |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、ノイラミニダーゼ阻害薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。ノイラミニダーゼ阻害薬の種類別市場規模（オセルタミビル、ザナミビル、ペラミビル、ラニナミビル）、用途別市場規模（病院薬局、小売薬局、オンライン薬局、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Roche、Daiichi Sankyo、GSK、Gilead Sciences ・地域別グローバル市場分析 2015年-2020年 ・ノイラミニダーゼ阻害薬の北米市場（アメリカ、カナダ、メキシコ） ・ノイラミニダーゼ阻害薬のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・ノイラミニダーゼ阻害薬のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・ノイラミニダーゼ阻害薬の南米市場（ブラジル、アルゼンチン） ・ノイラミニダーゼ阻害薬の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：オセルタミビル、ザナミビル、ペラミビル、ラニナミビル ・用途別分析：病院薬局、小売薬局、オンライン薬局、その他 ・地域別市場規模予測 2021年-2025年 ・調査の結果・結論 |
Market Overview
The Neuraminidase Inhibitors Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
The global Neuraminidase Inhibitors Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx%% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
Market segmentation
Neuraminidase Inhibitors Drug market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Neuraminidase Inhibitors Drug market has been segmented into:
Oseltamivir
Zanamivir
Peramivir
Laninamivir
By Application, Neuraminidase Inhibitors Drug has been segmented into:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Neuraminidase Inhibitors Drug market presented in the report. This section sheds light on the sales growth of different regional and country-level Neuraminidase Inhibitors Drug markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Neuraminidase Inhibitors Drug market.
The report offers in-depth assessment of the growth and other aspects of the Neuraminidase Inhibitors Drug market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Competitive Landscape and Neuraminidase Inhibitors Drug Market Share Analysis
Neuraminidase Inhibitors Drug competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Neuraminidase Inhibitors Drug sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Neuraminidase Inhibitors Drug sales, revenue and market share for each player covered in this report.
The major players covered in Neuraminidase Inhibitors Drug are:
Roche
Daiichi Sankyo
GSK
Gilead Sciences
Among other players domestic and global, Neuraminidase Inhibitors Drug market share data is available for global, North America, Europe, Asia-Pacific, Middle East & Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
1 Neuraminidase Inhibitors Drug Market Overview
1.1 Product Overview and Scope of Neuraminidase Inhibitors Drug
1.2 Classification of Neuraminidase Inhibitors Drug by Type
1.2.1 Global Neuraminidase Inhibitors Drug Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Neuraminidase Inhibitors Drug Revenue Market Share by Type in 2019
1.2.3 Oseltamivir
1.2.4 Zanamivir
1.2.5 Peramivir
1.2.6 Laninamivir
1.3 Global Neuraminidase Inhibitors Drug Market by Application
1.3.1 Overview: Global Neuraminidase Inhibitors Drug Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacy
1.3.5 Others
1.4 Global Neuraminidase Inhibitors Drug Market by Regions
1.4.1 Global Neuraminidase Inhibitors Drug Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Neuraminidase Inhibitors Drug (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Neuraminidase Inhibitors Drug Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Neuraminidase Inhibitors Drug Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Neuraminidase Inhibitors Drug Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Neuraminidase Inhibitors Drug Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Neuraminidase Inhibitors Drug Status and Prospect (2015-2025)
2 Company Profiles
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche SWOT Analysis
2.1.4 Roche Product and Services
2.1.5 Roche Neuraminidase Inhibitors Drug Revenue, Gross Margin and Market Share (2018-2019)
2.2 Daiichi Sankyo
2.2.1 Daiichi Sankyo Details
2.2.2 Daiichi Sankyo Major Business
2.2.3 Daiichi Sankyo SWOT Analysis
2.2.4 Daiichi Sankyo Product and Services
2.2.5 Daiichi Sankyo Neuraminidase Inhibitors Drug Revenue, Gross Margin and Market Share (2018-2019)
2.3 GSK
2.3.1 GSK Details
2.3.2 GSK Major Business
2.3.3 GSK SWOT Analysis
2.3.4 GSK Product and Services
2.3.5 GSK Neuraminidase Inhibitors Drug Revenue, Gross Margin and Market Share (2018-2019)
2.4 Gilead Sciences
2.4.1 Gilead Sciences Details
2.4.2 Gilead Sciences Major Business
2.4.3 Gilead Sciences SWOT Analysis
2.4.4 Gilead Sciences Product and Services
2.4.5 Gilead Sciences Neuraminidase Inhibitors Drug Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Neuraminidase Inhibitors Drug Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Neuraminidase Inhibitors Drug Players Market Share
3.2.2 Top 10 Neuraminidase Inhibitors Drug Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Neuraminidase Inhibitors Drug Revenue and Market Share by Regions
4.2 North America Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
4.3 Europe Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
4.5 South America Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
5 North America Neuraminidase Inhibitors Drug Revenue by Countries
5.1 North America Neuraminidase Inhibitors Drug Revenue by Countries (2015-2020)
5.2 USA Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
5.3 Canada Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
5.4 Mexico Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
6 Europe Neuraminidase Inhibitors Drug Revenue by Countries
6.1 Europe Neuraminidase Inhibitors Drug Revenue by Countries (2015-2020)
6.2 Germany Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
6.3 UK Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
6.4 France Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
6.5 Russia Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
6.6 Italy Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Neuraminidase Inhibitors Drug Revenue by Countries
7.1 Asia-Pacific Neuraminidase Inhibitors Drug Revenue by Countries (2015-2020)
7.2 China Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
7.3 Japan Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
7.4 Korea Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
7.5 India Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
8 South America Neuraminidase Inhibitors Drug Revenue by Countries
8.1 South America Neuraminidase Inhibitors Drug Revenue by Countries (2015-2020)
8.2 Brazil Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
8.3 Argentina Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Neuraminidase Inhibitors Drug by Countries
9.1 Middle East & Africa Neuraminidase Inhibitors Drug Revenue by Countries (2015-2020)
9.2 Saudi Arabia Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
9.3 UAE Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
9.4 Egypt Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
9.5 South Africa Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Neuraminidase Inhibitors Drug Revenue and Market Share by Type (2015-2020)
10.2 Global Neuraminidase Inhibitors Drug Market Forecast by Type (2019-2024)
10.3 Oseltamivir Revenue Growth Rate (2015-2025)
10.4 Zanamivir Revenue Growth Rate (2015-2025)
10.5 Peramivir Revenue Growth Rate (2015-2025)
10.6 Laninamivir Revenue Growth Rate (2015-2025)
11 Global Neuraminidase Inhibitors Drug Market Segment by Application
11.1 Global Neuraminidase Inhibitors Drug Revenue Market Share by Application (2015-2020)
11.2 Neuraminidase Inhibitors Drug Market Forecast by Application (2019-2024)
11.3 Hospital Pharmacy Revenue Growth (2015-2020)
11.4 Retail Pharmacy Revenue Growth (2015-2020)
11.5 Online Pharmacy Revenue Growth (2015-2020)
11.6 Others Revenue Growth (2015-2020)
12 Global Neuraminidase Inhibitors Drug Market Size Forecast (2021-2025)
12.1 Global Neuraminidase Inhibitors Drug Market Size Forecast (2021-2025)
12.2 Global Neuraminidase Inhibitors Drug Market Forecast by Regions (2021-2025)
12.3 North America Neuraminidase Inhibitors Drug Revenue Market Forecast (2021-2025)
12.4 Europe Neuraminidase Inhibitors Drug Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Neuraminidase Inhibitors Drug Revenue Market Forecast (2021-2025)
12.6 South America Neuraminidase Inhibitors Drug Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Neuraminidase Inhibitors Drug Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
Table 1. Global Neuraminidase Inhibitors Drug Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Neuraminidase Inhibitors Drug by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Neuraminidase Inhibitors Drug Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Neuraminidase Inhibitors Drug Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Global Neuraminidase Inhibitors Drug Market Size and Growth Estimation in Various Scenarios in 2020
Table 6. Roche Corporate Information, Location and Competitors
Table 7. Roche Neuraminidase Inhibitors Drug Major Business
Table 8. Roche Neuraminidase Inhibitors Drug Total Revenue (USD Million) (2017-2018)
Table 9. Roche SWOT Analysis
Table 10. Roche Neuraminidase Inhibitors Drug Product and Solutions
Table 11. Roche Neuraminidase Inhibitors Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 12. Daiichi Sankyo Corporate Information, Location and Competitors
Table 13. Daiichi Sankyo Neuraminidase Inhibitors Drug Major Business
Table 14. Daiichi Sankyo Neuraminidase Inhibitors Drug Total Revenue (USD Million) (2018-2019)
Table 15. Daiichi Sankyo SWOT Analysis
Table 16. Daiichi Sankyo Neuraminidase Inhibitors Drug Product and Solutions
Table 17. Daiichi Sankyo Neuraminidase Inhibitors Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 18. GSK Corporate Information, Location and Competitors
Table 19. GSK Neuraminidase Inhibitors Drug Major Business
Table 20. GSK Neuraminidase Inhibitors Drug Total Revenue (USD Million) (2017-2018)
Table 21. GSK SWOT Analysis
Table 22. GSK Neuraminidase Inhibitors Drug Product and Solutions
Table 23. GSK Neuraminidase Inhibitors Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 24. Gilead Sciences Corporate Information, Location and Competitors
Table 25. Gilead Sciences Neuraminidase Inhibitors Drug Major Business
Table 26. Gilead Sciences Neuraminidase Inhibitors Drug Total Revenue (USD Million) (2017-2018)
Table 27. Gilead Sciences SWOT Analysis
Table 28. Gilead Sciences Neuraminidase Inhibitors Drug Product and Solutions
Table 29. Gilead Sciences Neuraminidase Inhibitors Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 30. Global Neuraminidase Inhibitors Drug Revenue (Million USD) by Players (2015-2020)
Table 31. Global Neuraminidase Inhibitors Drug Revenue Share by Players (2015-2020)
Table 32. Global Neuraminidase Inhibitors Drug Revenue (Million USD) by Regions (2015-2020)
Table 33. Global Neuraminidase Inhibitors Drug Revenue Market Share by Regions (2015-2020)
Table 34. North America Neuraminidase Inhibitors Drug Revenue by Countries (2015-2020)
Table 35. North America Neuraminidase Inhibitors Drug Revenue Market Share by Countries (2015-2020)
Table 36. Europe Neuraminidase Inhibitors Drug Revenue (Million USD) by Countries (2015-2020)
Table 37. Asia-Pacific Neuraminidase Inhibitors Drug Revenue (Million USD) by Countries (2015-2020)
Table 38. South America Neuraminidase Inhibitors Drug Revenue by Countries (2015-2020)
Table 39. South America Neuraminidase Inhibitors Drug Revenue Market Share by Countries (2015-2020)
Table 40. Middle East and Africa Neuraminidase Inhibitors Drug Revenue (Million USD) by Countries (2015-2020)
Table 41. Middle East and Africa Neuraminidase Inhibitors Drug Revenue Market Share by Countries (2015-2020)
Table 42. Global Neuraminidase Inhibitors Drug Revenue (Million USD) by Type (2015-2020)
Table 43. Global Neuraminidase Inhibitors Drug Revenue Share by Type (2015-2020)
Table 44. Global Neuraminidase Inhibitors Drug Revenue Forecast by Type (2021-2025)
Table 45. Global Neuraminidase Inhibitors Drug Revenue by Application (2015-2020)
Table 46. Global Neuraminidase Inhibitors Drug Revenue Share by Application (2015-2020)
Table 47. Global Neuraminidase Inhibitors Drug Revenue Forecast by Application (2021-2025)
Table 48. Global Neuraminidase Inhibitors Drug Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Neuraminidase Inhibitors Drug Picture
Figure 2. Global Neuraminidase Inhibitors Drug Revenue Market Share by Type in 2019
Figure 3. Oseltamivir Picture
Figure 4. Zanamivir Picture
Figure 5. Peramivir Picture
Figure 6. Laninamivir Picture
Figure 7. Neuraminidase Inhibitors Drug Revenue Market Share by Application in 2019
Figure 8. Hospital Pharmacy Picture
Figure 9. Retail Pharmacy Picture
Figure 10. Online Pharmacy Picture
Figure 11. Others Picture
Figure 12. Global Neuraminidase Inhibitors Drug Revenue (USD Million) and Growth Rate (2015-2025)
Figure 13. North America Neuraminidase Inhibitors Drug Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Europe Neuraminidase Inhibitors Drug Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Asia-Pacific Neuraminidase Inhibitors Drug Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. South America Neuraminidase Inhibitors Drug Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Middle East and Africa Neuraminidase Inhibitors Drug Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Global Neuraminidase Inhibitors Drug Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. Global Neuraminidase Inhibitors Drug Revenue Share by Players in 2019
Figure 20. Global Top 5 Players Neuraminidase Inhibitors Drug Revenue Market Share in 2019
Figure 21. Global Top 10 Players Neuraminidase Inhibitors Drug Revenue Market Share in 2019
Figure 22. Key Players Market Share Trend
Figure 23. Global Neuraminidase Inhibitors Drug Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 24. Global Neuraminidase Inhibitors Drug Revenue Market Share by Regions (2015-2020)
Figure 25. Global Neuraminidase Inhibitors Drug Revenue Market Share by Regions in 2018
Figure 26. North America Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
Figure 27. Europe Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
Figure 28. Asia-Pacific Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
Figure 29. South America Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
Figure 30. Middle East and Africa Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
Figure 31. North America Neuraminidase Inhibitors Drug Revenue Market Share by Countries (2015-2020)
Figure 32. North America Neuraminidase Inhibitors Drug Revenue Market Share by Countries in 2019
Figure 33. USA Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
Figure 34. Canada Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
Figure 35. Mexico Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
Figure 36. Europe Neuraminidase Inhibitors Drug Revenue Market Share by Countries (2015-2020)
Figure 37. Europe Neuraminidase Inhibitors Drug Revenue Market Share by Countries in 2019
Figure 38. Germany Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
Figure 39. UK Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
Figure 40. France Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
Figure 41. Russia Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
Figure 42. Italy Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
Figure 43. Asia-Pacific Neuraminidase Inhibitors Drug Revenue Market Share by Countries (2015-2020)
Figure 44. Asia-Pacific Neuraminidase Inhibitors Drug Revenue Market Share by Countries in 2019
Figure 45. China Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
Figure 46. Japan Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
Figure 47. Korea Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
Figure 48. India Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
Figure 49. Southeast Asia Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
Figure 50. South America Neuraminidase Inhibitors Drug Revenue Market Share by Countries (2015-2020)
Figure 51. South America Neuraminidase Inhibitors Drug Revenue Market Share by Countries in 2019
Figure 52. Brazil Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
Figure 53. Argentina Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
Figure 54. Middle East and Africa Neuraminidase Inhibitors Drug Revenue Market Share by Countries (2015-2020)
Figure 55. Middle East and Africa Neuraminidase Inhibitors Drug Revenue Market Share by Countries in 2019
Figure 56. Saudi Arabia Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
Figure 57. UAE Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
Figure 58. Egypt Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
Figure 59. South Africa Neuraminidase Inhibitors Drug Revenue and Growth Rate (2015-2020)
Figure 60. Global Neuraminidase Inhibitors Drug Revenue Share by Type (2015-2020)
Figure 61. Global Neuraminidase Inhibitors Drug Revenue Share by Type in 2019
Figure 62. Global Neuraminidase Inhibitors Drug Market Share Forecast by Type (2021-2025)
Figure 63. Global Oseltamivir Revenue Growth Rate (2015-2020)
Figure 64. Global Zanamivir Revenue Growth Rate (2015-2020)
Figure 65. Global Peramivir Revenue Growth Rate (2015-2020)
Figure 66. Global Laninamivir Revenue Growth Rate (2015-2020)
Figure 67. Global Neuraminidase Inhibitors Drug Revenue Share by Application (2015-2020)
Figure 68. Global Neuraminidase Inhibitors Drug Revenue Share by Application in 2019
Figure 69. Global Neuraminidase Inhibitors Drug Market Share Forecast by Application (2021-2025)
Figure 70. Global Hospital Pharmacy Revenue Growth Rate (2015-2020)
Figure 71. Global Retail Pharmacy Revenue Growth Rate (2015-2020)
Figure 72. Global Online Pharmacy Revenue Growth Rate (2015-2020)
Figure 73. Global Others Revenue Growth Rate (2015-2020)
Figure 74. Global Neuraminidase Inhibitors Drug Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 75. Global Neuraminidase Inhibitors Drug Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 76. Global Neuraminidase Inhibitors Drug Revenue Market Share Forecast by Regions (2021-2025)
Figure 77. North America Neuraminidase Inhibitors Drug Revenue Market Forecast (2021-2025)
Figure 78. Europe Neuraminidase Inhibitors Drug Revenue Market Forecast (2021-2025)
Figure 79. Asia-Pacific Neuraminidase Inhibitors Drug Revenue Market Forecast (2021-2025)
Figure 80. South America Neuraminidase Inhibitors Drug Revenue Market Forecast (2021-2025)
Figure 81. Middle East and Africa Neuraminidase Inhibitors Drug Revenue Market Forecast (2021-2025)
Figure 82. Sales Channel: Direct Channel vs Indirect Channel
酵素阻害剤の世界市場2020年：メーカー別、地域別、種類・用途別 Market Overview The global Enzyme Inhibitors market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 0.8% in the forecast period of 2020 to 2025 and will expected to reach USD 152460 million by 2025, from USD 147910 million in 2019. The Enzyme Inhibitors …- 副腎皮質ステロイド阻害剤の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The Adrenal Corticosteroid Inhibitors market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain o…
- プロテアソーム阻害剤の世界市場2020年：メーカー別、地域別、種類・用途別 Market Overview The global Proteasome Inhibitors market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Proteasome Inhibitors m…
- 重合禁止剤の世界市場2020年：メーカー別、地域別、種類・用途別 Market Overview The global Polymerization Inhibitors market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Polymerization Inhi…
- インフルエンザ（インフルエンザ）抗ウイルス薬の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The Influenza (Flu) Antiviral Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain opt…